On July 18, the Class 1 innovative drug Jikeshu (generic name: Maxiluoshavir Tablets) was officially approved for marketing by the National Medical Products Administration (NMPA). It is indicated for the treatment of uncomplicated influenza A and B in otherwise healthy adults. Jikeshu is a new-generation targeted inhibitor of influenza virus RNA polymerase PA independently developed in China with global intellectual property rights. The entire treatment course requires only a single dose. The approval of Jikeshu not only marks a major breakthrough in China’s innovative R&D of anti-influenza drugs but also enhances its competitiveness in the global market, providing a new option for clinical treatment.

 

Jikeshu: Combating Influenza with a Single Dose

 

As a novel inhibitor targeting the PA subunit of the influenza virus RNA polymerase, Jikeshu (generic name: Maxiluoshavir Tablets) exerts its antiviral effect by specifically inhibiting viral mRNA transcription, directly interfering with a core step in viral genome replication. Clinical studies have demonstrated its sustained antiviral activity.

 

The Phase II/III clinical trials of Jikeshu were led by renowned experts including Professor Zhang Wenhong, Director of the Department of Infectious Diseases at Huashan Hospital affiliated with Fudan University, and Professor Zhu Huadong, Director of the Emergency Department at Peking Union Medical College Hospital. The related findings were published in the top-tier journal Clinical Microbiology and Infection, providing further scientific support for clinical application.

 

 

One-Dose Full Course with Long-Lasting Effects: Studies have shown that Jikeshu has a long half-life and high plasma exposure levels, supporting a one-dose full course without the need for weight-based dosage adjustments. This offers greater convenience and sustained health protection.

Fever Reduction Within 1 Day, Rapid Relief of Influenza Symptoms: After taking Jikeshu, peak plasma concentration is reached within 3 hours, indicating rapid onset of action. Fever reduction occurs within one day, and all influenza symptoms are significantly improved within 39.4 hours, quickly clearing the influenza virus and shortening the disease course.

Low Incidence of Adverse Reactions, A New Treatment Option: Studies also revealed a low incidence of Jikeshu-related adverse events. As it is metabolized through non-CYP enzyme pathways, it has minimal interactions with other drugs, providing patients with a new treatment option.

Additionally, the clinical study subjects for Jikeshu were exclusively Chinese patients, making the clinical medication basis more targeted and applicable to the physiological characteristics of the Chinese population. This offers a "one-dose solution" Chinese treatment strategy for combating influenza.

 

JumpCan Pharmaceutical: Innovation-Driven, Benefiting Patients

 

JumpCan Pharmaceutical has long kept pace with evolving patient needs, focusing on medium- to long-term development strategies and actively pursuing independent R&D of innovative drugs in both traditional Chinese and Western medicine. By enabling expansion through business development, the company has established an R&D system that combines independent innovation and collaborative research, committed to providing patients with diverse innovative treatments.

 

In 2023, JumpCan Pharmaceutical entered into a strategic partnership with Zenshine for the registration, production, promotion, channel management, and commercial sales of Jikeshu. JumpCan Pharmaceutical holds exclusive promotion and sales rights for Jikeshu in mainland China, enhancing its accessibility in clinical practice and aiming to provide more differentiated treatment options for influenza patients.

 

The approval and launch of Jikeshu represent another milestone in JumpCan Pharmaceutical’s innovation journey and a new starting point for its deep commitment to the health sector. Moving forward, guided by its vision of "Build a joyful and vibrant life together", JumpCan Pharmaceutical will accelerate the transformation of innovative achievements, promote sustainable enterprise development, and collaborate to enhance life quality and health well-being, ensuring that more innovative outcomes benefit patients.

 

References:

[1] Jikeshu Prescribing Information
[2] Zhang W. et al. Efficacy and safety of ZX-7101A, an inhibitor of influenza cap-dependent endonuclease, in adults with uncomplicated influenza: a randomized, double-blind, placebo-controlled phase 2/3 trial. Clin Microbiol Infect. 2025 Feb;31(2):274-281.
[3] Zhang J. et al. Safety, tolerability, and pharmacokinetics of a novel anti-influenza agent ZX-7101A tablets in healthy Chinese participants: A first-in-human phase I clinical study. Int J Antimicrob Agents. 2025 Jan;65(1):10738.
[4] Zenshine Official WeChat Account: Zenshine Partners with JumpCan Pharmaceutical to Accelerate Commercial Development of Core Products [EB/OL]. (Aug 7, 2023  10:43:00). https://mp.weixin.qq.com/s/ewRGIl7-oQIIF8s0RmkHnA.